Marshall Wace, LLP Aclaris Therapeutics, Inc. Transaction History

Marshall Wace, LLP

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	BUY	$7.89 - $10.64 $240,037 - $323,700	30,423 New	30,423 $315,000
Q4 2021 Feb 14, 2022	SELL	$12.27 - $18.49 $167,105 - $251,815	-13,619 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$13.38 - $18.8 $182,222 - $256,037	13,619 New	13,619 $245,000
Q2 2021 Aug 13, 2021	SELL	$17.08 - $29.6 $625,332 - $1.08 Million	-36,612 Closed	0 $0
Q1 2021 May 17, 2021	BUY	$5.86 - $27.73 $214,546 - $1.02 Million	36,612 New	36,612 $923,000
Q2 2019 Aug 14, 2019	SELL	$2.13 - $7.06 $36,731 - $121,749	-17,245 Closed	0 $0
Q1 2019 May 14, 2019	BUY	$5.63 - $7.84 $97,089 - $135,200	17,245 New	17,245 $103,000

50.7M

30.6K

Ticker ACRS
Exchange NASDAQ
Sector Healthcare
Industry Diagnostics & Research
Shares Outstandng 66,671,800
Market Cap $255M
Description
Aclaris Therapeutics, Inc. operates a clinical-stage biopharmaceutical company, develops novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments: Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing innovative therapies to address significant ...

Get notified when there are updates to the investment portfolio of Marshall Wace, LLP, based on Form 13F filings with the SEC.

Stay updated on Marshall Wace, LLP with notifications on news.